Royalty Pharma Sub-Manager, LLC
13F Reported Value
ⓘ$172.8M
Holdings
4
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Royalty Pharma Sub-Manager, LLC disclosed 4 positions worth $172.8M in its Form 13F-HR for Q1 2026, led by $CYTK (CYTOKINETICS INC) at 37.4% of the equity portfolio, followed by $BCAX and $BCRX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Royalty Pharma Sub-Manager, LLC’s Form 13F-HR filing with the SEC under CIK 2081668.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 28.0#2,453
Quality
$64.6M980,392 sh - —
Quality
$46.7M2,388,150 sh - 37.2#2,063
Quality
$36.6M3,846,154 sh - —
Quality
$24.8M2,936,507 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 CYTOKINETICS INC$CYTK | 28.0#2,453 | $64.6M | 980,392 |
 Bicara Therapeutics Inc.$BCAX | — | $46.7M | 2,388,150 |
 BIOCRYST PHARMACEUTICALS INC$BCRX | 37.2#2,063 | $36.6M | 3,846,154 |
 Biohaven Ltd.$BHVN | — | $24.8M | 2,936,507 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Royalty Pharma Sub-Manager, LLC's 4 positions.
Showing top 4 of 4 holdings.
Sector Allocation
Healthcare
$172.8M
Full Holdings — Royalty Pharma Sub-Manager, LLC (Q1 2026)
All 4 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Royalty Pharma Sub-Manager, LLC including:
Track Royalty Pharma Sub-Manager, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Royalty Pharma Sub-Manager, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Royalty Pharma Sub-Manager, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Royalty Pharma Sub-Manager, LLC (SEC CIK: 2081668), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Royalty Pharma Sub-Manager, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.